{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:16:21Z","timestamp":1789877781131,"version":"4.0.1"},"reference-count":24,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T00:00:00Z","timestamp":1553817600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0569-1","type":"journal-article","created":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T06:02:27Z","timestamp":1553839347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations"],"prefix":"10.1136","volume":"7","author":[{"given":"Paolo A.","family":"Ascierto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariaelena","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio M.","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Mallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Simeone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Madonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrich","family":"Roder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senait","family":"Asmellash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Roder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8136-6167","authenticated-orcid":false,"given":"Julia","family":"Grigorieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,3,29]]},"reference":[{"key":"569_CR1","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","volume":"17","author":"PB Chapman","year":"1999","unstructured":"Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745\u201351.","journal-title":"J Clin Oncol"},{"key":"569_CR2","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","volume":"34","author":"GV Long","year":"2016","unstructured":"Long GV, Weber JS, Infante JR, et al. Overall survival and durable responses in patients with BRAF V600\u2013mutant metastatic melanoma receiving Dabrafenib combined with Trametinib. J Clin Oncol. 2016;34:871\u20138.","journal-title":"J Clin Oncol"},{"key":"569_CR3","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19:1315\u201327.","journal-title":"Lancet Oncol"},{"key":"569_CR4","doi-asserted-by":"crossref","unstructured":"Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018.","DOI":"10.1016\/S1470-2045(18)30700-9"},{"key":"569_CR5","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390:1853\u201362.","journal-title":"Lancet"},{"key":"569_CR6","doi-asserted-by":"crossref","unstructured":"Long GV, Schachter J, Ribas A, et al. 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. Journal of Clinical Ocology. 2018;36.","DOI":"10.1200\/JCO.2018.36.15_suppl.9503"},{"key":"569_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323.","journal-title":"N Engl J Med"},{"key":"569_CR8","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of Long-term survival data from phase II and phase III trials of Ipilimumab in Unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889\u201394.","journal-title":"J Clin Oncol"},{"key":"569_CR9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330.","journal-title":"N Engl J Med"},{"key":"569_CR10","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521\u201332.","journal-title":"N Engl J Med"},{"key":"569_CR11","doi-asserted-by":"crossref","unstructured":"Dummer R, Ascierto PA, Gogas H, et al. Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma. In: 2018 ASCO Annual Meeting. Chicago, IL: J Clin Oncol; 2018:abst 9504.","DOI":"10.1200\/JCO.2018.36.15_suppl.9504"},{"key":"569_CR12","doi-asserted-by":"publisher","first-page":"mdy289-mdy","DOI":"10.1093\/annonc\/mdx779","volume":"29","author":"PA Ascierto","year":"2018","unstructured":"Ascierto PA, Ferrucci PF, Stephens R, et al. KEYNOTE-022 part 3: phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma. Ann Oncol. 2018;29:mdy289-mdy.","journal-title":"Ann Oncol"},{"key":"569_CR13","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/pcmr.12383","volume":"28","author":"DR Minor","year":"2015","unstructured":"Minor DR, Puzanov I, Callahan MK, Hug BA, Hoos A. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. Pigment cell & melanoma research. 2015;28:611\u20132.","journal-title":"Pigment cell & melanoma research"},{"key":"569_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165:35\u201344.","journal-title":"Cell"},{"key":"569_CR15","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1200\/JCO.2013.52.1377","volume":"32","author":"S Hu-Lieskovan","year":"2014","unstructured":"Hu-Lieskovan S, Robert L, Homet Moreno B, Ribas A. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol. 2014;32:2248\u201354.","journal-title":"J Clin Oncol"},{"key":"569_CR16","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","volume":"31","author":"JS Weber","year":"2013","unstructured":"Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013;31:4311\u20138.","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"569_CR17","doi-asserted-by":"publisher","first-page":"P103","DOI":"10.1186\/2051-1426-3-S2-P103","volume":"3","author":"J Weber","year":"2015","unstructured":"Weber J, Martinez A, Roder H, et al. Pre-treatment patient selection for nivolumab benefit based on serum mass spectra. Journal for immunotherapy of cancer. 2015;3(Suppl 2):P103.","journal-title":"Journal for immunotherapy of cancer"},{"key":"569_CR18","doi-asserted-by":"publisher","first-page":"S1322","DOI":"10.1016\/j.jtho.2016.11.1870","volume":"12","author":"F Grossi","year":"2017","unstructured":"Grossi F, Rijavec E, Biello F, et al. Evaluation of a pretreatment serum tests for nivolumab benefit in patients with non-small cell lung cancer. J Thorac Oncol. 2017;12:S1322.","journal-title":"J Thorac Oncol"},{"key":"569_CR19","first-page":"5","volume":"102","author":"R Zahorec","year":"2001","unstructured":"Zahorec R. Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102:5\u201314.","journal-title":"Bratisl Lek Listy"},{"key":"569_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40425-018-0383-1","volume":"6","author":"M Capone","year":"2018","unstructured":"Capone M, Giannarelli D, Mallardo D, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 2018;6:74.","journal-title":"J Immunother Cancer"},{"key":"569_CR21","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/annonc\/mdx059","volume":"29","author":"PF Ferrucci","year":"2018","unstructured":"Ferrucci PF, Ascierto PA, Pigozzo J, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol. 2018;29:524.","journal-title":"Ann Oncol"},{"key":"569_CR22","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"569_CR23","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/ni.1655","volume":"9","author":"MM Markiewski","year":"2008","unstructured":"Markiewski MM, DeAngelis RA, Benencia F, et al. Modulation of the antitumor immune response by complement. Nat Immunol. 2008;9:1225\u201335.","journal-title":"Nat Immunol"},{"key":"569_CR24","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrclinonc.2015.105","volume":"12","author":"SM Crusz","year":"2015","unstructured":"Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015;12:584\u201396.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0569-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0569-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0569-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:47:24Z","timestamp":1601056044000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0569-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,29]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["569"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0569-1","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,29]]},"assertion":[{"value":"9 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of the Istituto Nazionale Tumori IRCCS Fondazione \u201cG. Pascale\u201d with registration number 35\/16 and all patients signed informed consent for the use of biological samples for research purposes.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"P.A: Consulting or Advisory Role for BMS, Roche-Genentech, MSD, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, Genmab, Newlink Genetics, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofi, Idera, Ultimovacs; Research funds from BMS, Roche-Genentech, Array; Travel support by MSD.A.G.: Consulting or Advisory Role for BMS, MSD, Novartis; Travel support by BMS, MSD, Merck Serono, Roche.HR, JR, JG, KM, SA, CO are\u00a0or were full time employees of Biodesix and have\/had stock options of the company.Other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"91"}}